Page 2 - Eli Lilly

Anti-obesity mkt heats up as Mounjaro's Kwikpen version gets India approval

With CDSCO approval, Mounjaro to be available in a Kwikpen format; this comes a day after Wegovy's India launch, intensifying competition in weight-loss treatment

India approves Eli Lilly's Mounjaro pen for diabetes, weight control

Eli Lilly's once-weekly KwikPen format for Mounjaro has been approved in India, offering an easier delivery system for type 2 diabetes and chronic weight management

Novo Nordisk launches Wegovy in India to rival Eli Lilly's weight-loss drug

Wegovy enters the Indian market as the first GLP-1 drug approved for both weight loss and cardiovascular risk reduction, competing with Eli Lilly's Mounjaro

Eli Lilly's weekly insulin efsitora shows positive results in Phase 3

The company plans to submit efsitora, its once-weekly insulin for type 2 diabetes, to global regulators by end-2026 following positive Phase 3 trial outcomes

India's response to obesity drug Mounjaro 'positive', says Eli Lilly

Mounjaro has sold more than 81,570 units in India, totalling about ₹23.94 crore ($2.76 million) as of May, with the drug logging a 60 per cent rise in overall sales between April and May

Eli Lilly to acquire gene-editing firm Verve Therapeutics for $1.3 billion

Lilly has struck multiple partnership deals with gene-editing companies in the last two years to expand its portfolio beyond its blockbuster weight-loss and diabetes drugs

Eli Lilly's weight loss drug Mounjaro sales bulk up 60% on dosage upgrade

It logged value sales worth Rs 12.61 crore in May, compared to Rs 7.88 crore in April.

Lilly's obesity drug Mounjaro's sales rise 60% in India amid rising demand

The US drugmaker sold ₹12.6 crore ($1.5 million) worth of the injections last month, according to market analysis firm Pharmarack Technologies

Why Ozempic maker Novo Nordisk is losing its lead in weight-loss drugs

The Danish drugmaker led the obesity revolution with Ozempic and Wegovy but now lags Eli Lilly in efficacy, trials, and strategy in a $150-bn market

Eli Lilly's tirzepatide shows superior weight loss to Novo's semaglutide

Phase 3b trial finds Lilly's tirzepatide delivers higher average weight loss and waist reduction than Novo's semaglutide in people with obesity or overweight

Eli Lilly's first weight-loss pill shows success in initial Phase 3 trials

Lilly CEO says if approved, drug could be manufactured and launched at scale globally

Why Mounjaro's India entry has doctors and patients picking up the phone

With obesity on the rise, Eli Lilly's weight-loss injection triggers a rush of consultations as Indians seek safer, cheaper options to black-market drugs

Booster shot: Mounjaro may emerge as a sweet pill for Eli Lilly in India

Analysts say the diabetes and obesity drug can be a Rs 500 crore opportunity for the firm

Weight-loss drug Mounjaro now available in India: All you need to know

Mounjaro, Eli Lilly's diabetes and obesity drug, is now available in India at a fraction of its US price. It offers treatment for weight loss and diabetes control, but watch out for the side effects

Eli Lilly launches blockbuster anti-obesity drug Mounjaro in India. Prices here

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what you need to know

Lilly forecasts 2025 profit above estimates on weight-loss drug strength

The forecast comes weeks after the drugmaker stunned investors with weaker-than-expected sales for its weight-loss drug Zepbound for the second straight quarter

Eli Lilly to buy cancer drugmaker Scorpion Therapeutics for up to $2.5 bn

Lilly will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials for breast cancer and other advanced solid tumors

US pharma major Eli Lilly to establish second Indian GCC in Hyderabad

Company plans to employ 1,000-1,500 skilled professionals; GCC to focus on automation, AI

Eli Lilly to set up global capability centre in Hyderabad, hire 1K people

Pharma major Eli Lilly and Company on Thursday said it plans to establish a new global capability centre in Hyderabad and hire over 1,000 people to strengthen its digital strategy and service delivery. The Hyderabad global capability centre (GCC) will be known as Lilly Capability Centre India (LCCI) Hyderabad and will initially focus on expanding Lilly's capabilities in automation, artificial intelligence, software product engineering and cloud computing to deliver advanced technology solutions that meet the evolving needs of Lilly's business worldwide, the Eli Lilly and Company (Lilly) said in a statement. Lilly will be recruiting more than 1,000 highly-skilled team members to strengthen the company's digital strategy and service delivery, it added. The company further said it plans to employ around 1,000 to 1,500 highly-skilled professionals including technology engineers and data scientists. Recruitment for the new site is underway, and the centre is expected to be operational b

In weight loss battle, Novo and Lilly face offensive from licenced copies

Since Novo's blockbuster Ozempic diabetes treatment was approved in the United States in 2017, regulators have greenlighted 22 medicines containing its main ingredient in Bangladesh, Laos, Russia